Utility of Clot Formation and Lysis Assay to Monitor Global Coagulation State of Patients with Severe Acute Pancreatitis

Background Systemic inflammation affects hemostasis during severe acute pancreatitis (SAP). A hypercoagulable state occurs more frequently in SAP, which is not fully detected by traditional coagulation testing. Aims The aim of this study was to evaluate the contribution of clot formation and lysis (...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2012-05, Vol.57 (5), p.1399-1403
Main Authors: Zhu, Rongtao, Wei, Sidong, Wu, Chuanxin, Li, Shengwei, Gong, Jianping
Format: Article
Language:English
Subjects:
Adult
Aged
Biochemistry
Blood
Blood Coagulation Tests - methods
Blood Coagulation Tests - standards
Diagnosis, Computer-Assisted - methods
Female
Fibrin
Fibrin - analysis
Fibrin Fibrinogen Degradation Products - analysis
Fibrinogen - analysis
Fibrinolysis
Gastroenterology
Hepatology
Humans
Male
Medical examination
Medicine
Medicine & Public Health
Middle Aged
Monitoring, Physiologic - methods
Monitoring, Physiologic - standards
Oncology
Original Article
Pancreatitis
Pancreatitis - blood
Pancreatitis - complications
Plasminogen - analysis
Severity of Illness Index
Systemic Inflammatory Response Syndrome - blood
Systemic Inflammatory Response Syndrome - etiology
Thrombophilia - blood
Thrombophilia - diagnosis
Thrombophilia - etiology
Thrombosis - blood
Thrombosis - diagnosis
Thrombosis - etiology
Transplant Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Systemic inflammation affects hemostasis during severe acute pancreatitis (SAP). A hypercoagulable state occurs more frequently in SAP, which is not fully detected by traditional coagulation testing. Aims The aim of this study was to evaluate the contribution of clot formation and lysis (CloFAL) assay to improve monitoring of global coagulation in patients with SAP. Methods Twenty-five patients with SAP who were treated from December 2009 to April 2011 were studied. Plasma was collected at the time of admission, and CloFAL was measured using the CloFAL analyzer. The parameters evaluated include coagulation time (CT), fibrinolysis time (FT), and maximum amplitude (MA), from which the accelerating coagulation extent (ACE, MA/CT), accelerating fibrinolytic extent (AFE, MA/FT), and balance level exponent (BLE, ACE/AFE) were calculated. In addition, laboratory values for the traditional coagulation testing were measured. Values were compared to a control group of 20 healthy subjects. Results The MA, FT, ACE, and BLE values of the CloFAL assay were significantly increased in the SAP group compared to the control group ( p  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-012-2034-6